Endometrial Cancer – Global Drug Forecast and Market Analysis to 2030

EC is a uterine malignancy which is often diagnosed in the early stages of the disease due to the common symptom of post-menopausal bleeding. Due to the early diagnosis rate, surgery is the upfront treatment option for patients and only patients with high-risk of relapse are considered for adjuvant therapy with chemotherapy or hormone therapy. The unmet needs associated with EC arise for patients that relapse the upfront therapy since there is a lack of treatments available for advanced and relapsed patients. Rather, the guidelines recommend a plethora of off-label therapies which have been shown to benefit these patients but for which not approval currently exists. As a result, these patients are further limited by strict reimbursement regulations. Historically, EC was categorized by hormone driven or non-hormone driven disease however novel biomarkers are being tested and approved in EC which are resulting in multiple pipeline agents being explored. GlobalData is expecting a total of 5 new entrants to launch over the forecast period in the 8MM from 2020-2030.

KEY QUESTIONS ANSWERED

– Five late-stage pipeline agents and two label expansions are going to enter the EC market from 2020 onwards. What impact will these agents have on the market? Which of these drugs will have the highest peak sales, and why?

– What are the current unmet needs in EC, which pipeline agents are positioned to counter these unmet needs? What are the opportunities for R&D?

– What is the market outlook in the 8MM from 2020-2030? Considering major patent expiries, launch of new premium priced agents and expected label expansions.

Scope

Overview of EC including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.

Topline EC market revenue, annual cost of therapy, and major pipeline product sales in the forecast period.

Key topics covered include current treatment and pipeline therapies, unmet needs and opportunities, and the drivers and barriers affecting EC therapeutics sales in the 8MM.

Pipeline analysis: Comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs (Phase III).

Analysis of the current and future market competition in the global EC therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Key Highlights

The main drivers of growth include the anticipated launch of novel therapies, improved patient segmentation, label expansions of the projected market leading drugs and the increased disease incidence across the 8MM.

The main barriers to growth in the 8MM include the patent expiry of the market leading drugs and the strict regulations on reimbursement, particularly in Canada and Japan.

Among the late-stage pipeline products and marketed agents, marketed drug combinations immunotherapies are expected to generate the greatest revenues over the forecast period.

The most important unmet needs in the EC market include: the lack of approved therapies for advanced and relapsed patients and lack of patient segmentation after relapse.

Reasons to buy

The report will enable you to:

Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.

Develop business strategies by understanding the trends shaping and driving the global EC therapeutics market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global EC market in the future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Track drug sales in the global EC therapeutics market from 2019-2029.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Companies mentioned

AstraZeneca

Eisai

Genetech

GlaxoSmithKline

Karypharm

Merck & Co

Novartis

Pfizer

Roche

Table of Contents

Table of Contents

| About GlobalData

1 Endometrial Cancer: Executive Summary

1.1 Large Market Growth Forecast for the Endometrial Cancer Market During 2020-2030

1.2 Immunotherapy Set to Become the Standard of Care and Redefine Patient Segmentation

1.3 Launches of Novel Therapies Will Significantly Address the Current Lack of Approved Therapies and Patient Segmentation

1.4 Immunotherapy and Novel Drug Classes to Lead the Endometrial Cancer Market

1.5 What Do Physicians Think?

2 Introduction

2.1 Catalyst

2.2 Related Reports

2.3 Upcoming Reports

3 Disease Overview

3.1 Etiology and Pathophysiology

3.1.1 Etiology

3.1.2 Pathophysiology

3.1.3 Classification or Staging Systems

4 Epidemiology

4.1 Disease Background

4.2 Global and Historical Trends

4.3 Risk Factors and Comorbidities

4.4 Forecast Methodology

4.4.1 Sources

4.4.2 Forecast Assumptions and Methods

4.4.3 Diagnosed Incident Cases of Endometrial Cancer

4.4.4 Diagnosed Incident Cases of Endometrial Cancer by FIGO Stage at Diagnosis

4.4.5 Diagnosed Incident Cases of Endometrial Cancer by Subtype

4.4.6 Diagnosed Incident Cases of Endometrial Cancer by Associated Biomarker

4.4.7 Five-Year Diagnosed Prevalent Cases of Endometrial Cancer

4.5 Epidemiological Forecast for Endometrial Cancer (2020-2030)

4.5.1 Diagnosed Incident Cases of Endometrial Cancer

4.5.2 Age-Specific Diagnosed Incident Cases of Endometrial Cancer

4.5.3 Diagnosed Incident Cases of Endometrial Cancer by FIGO Stage

4.5.4 Diagnosed Incident Cases of Endometrial Cancer by Subtype

4.5.5 Diagnosed Incident Cases of Endometrial Cancer with Associated Biomarkers

4.5.6 Diagnosed Incident Cases of Endometrial Cancer with HER2 Positivity by FIGO Stage

4.5.7 Five-Year Diagnosed Prevalent Cases of Endometrial Cancer

4.6 Discussion

4.6.1 Epidemiological Forecast Insight

4.6.2 COVID-19 Impact

4.6.3 Limitations of Analysis

4.6.4 Strengths of Analysis

5 Disease Management

5.1 Diagnosis and Treatment Overview

5.2 KOL Insights on Disease Management

6 Competitive Assessment

6.1 Overview

7 Unmet Needs and Opportunity Assessment

7.1 Overview

7.2 Lack of Approved Therapies and Established Treatment Guidelines for Recurrent Patients

7.3 Establish Tumor Sequencing as Standard of Care

7.4 Define Patients Groups that Would Benefit from Maintenance Therapy

7.5 Treatment Alternatives for Patients who Cannot Tolerate Chemotherapy or Have Become Chemo-Resistant

8 R&D Strategies

8.1 Overview

8.1.1 Identify Optimal Immunotherapy Combination Strategies and Define Preferred Treatment per Line of Therapy

8.1.2 Introduction of Novel Mechanisms of Action and Targets

8.2 Clinical Trial Design

8.2.1 Precedent for EC Clinical Trial Design and Importance for Ongoing Clinical Trials

8.2.2 Limitations of Current Clinical Trials

9 Pipeline Assessment

9.1 Overview

9.2 Promising Drugs in Clinical Development

9.2.1 PD-1/PD-L1 Inhibitors Plus Chemotherapy Under Investigation with a Maintenance Component

9.2.2 PD-1/PD-L1 Inhibitor Combinations with Either Chemotherapy or Targeted Therapies, Without a Maintenance Component

9.2.3 Novel Drug Classes Targeting the Unresectable and Relapsed Population

9.2.4 Promising Novel Therapies in Early-Stage Development

10 Pipeline Valuation Analysis

10.1 Overview

10.2 Competitive Assessment

11 Current and Future Players

11.1 Overview

11.2 Deal-Making Trends

12 Market Outlook

12.1 Global Markets

12.1.1 Forecast

12.1.2 Drivers and Barriers – Global Issues

12.2 US

12.2.1 Forecast

12.2.2 Key Events

12.2.3 Drivers and Barriers

12.3 5EU

12.3.1 Forecast

12.3.2 Key Events

12.3.3 Drivers and Barriers

12.4 Japan

12.4.1 Forecast

12.4.2 Key Events

12.4.3 Drivers and Barriers

12.5 Canada

12.5.1 Forecast

12.5.2 Key Events

12.5.3 Drivers and Barriers

13 Appendix

13.1 Bibliography

13.2 Abbreviations

13.3 Methodology

13.3.1 Forecasting Methodology

13.4 Primary Research – KOLs Interviewed for This Report

13.4.1 KOLs

13.5 Primary Research – Prescriber Survey

13.6 About the Authors

13.6.1 Analyst

13.6.2 Therapy Area Director

13.6.3 Epidemiologist

13.6.4 Managing Epidemiologists

13.6.5 Global Director of Therapy Analysis and Epidemiology

13.6.6 Global Head and EVP of Healthcare Operations and Strategy

| Contact Us

List of Tables

Table 1: Endometrial Cancer: Key Metrics in the 8MM

Table 2: Stage Definitions for Endometrial Cancer

Table 3: Risk Factors for Endometrial Cancer

Table 4: 8MM, Diagnosed Incident Cases of Endometrial Cancer by Subtype, Women, Ages 18 Years, N, 2020

Table 5: Treatment Guidelines for Endometrial Cancer

Table 6: Endometrial Cancer Market – Global Drivers and Barriers, 2020-2030

Table 7: Key Events Impacting Sales for EC in the US, 2020-2030

Table 8: EC Market – Drivers and Barriers in the US, 2020-2030

Table 9: Key Events Impacting Sales for EC in the 5EU, 2020-2030

Table 10: EC Market – Drivers and Barriers in the 5EU, 2020-2030

Table 11: Key Events Impacting Sales for EC in Japan, 2020-2030

Table 12: Endometrial Cancer Market – Drivers and Barriers in Japan, 2020-2030

Table 13: Key Events Impacting Sales for EC in Canada, 2020-2030

Table 14: EC Market – Drivers and Barriers in Canada, 2020-2030

Table 15: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

Figure 1: Global Sales Forecast by Country for Endometrial Cancer in 2020 and 2030

Figure 2: Analysis of the Company Portfolio Gap in Endometrial Cancer During the Forecast Period

Figure 3: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to be Licensed for the Treatment of Endometrial Cancer During the Forecast Period

Figure 4: Impact of the Estrogen-Progesterone Cycle in Determining Endometrial Thickness

Figure 5: Prognostic Groups in Endometrial Cancer According to TCGA

Figure 6. 8MM, Diagnosed Incidence of Endometrial Cancer (Cases per 100,000 population), Women, Ages ≥18 Years, 2020 and 2030

Figure 7: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of Endometrial Cancer

Figure 8: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of Endometrial Cancer by FIGO Stage

Figure 9: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of Endometrial Cancer by Subtype

Figure 10: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of Endometrial Cancer with Associated Biomarker

Figure 11: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of Endometrial Cancer with HER2 Positivity by FIGO Stage

Figure 12: 8MM, Sources Used to Forecast the Five-Year Diagnosed Prevalent Cases of Endometrial Cancer

Figure 13: Diagnosed Incident Cases of Endometrial Cancer, 8MM, Women, Ages ≥18 years, 2020

Figure 14: 8MM, Diagnosed Incident Cases of Endometrial Cancer by Age, Women, N, 2020

Figure 15: 8MM, Diagnosed Incident Cases of Endometrial Cancer by FIGO Stage, Women, Ages ≥18 Years, N, 2020

Figure 16: 8MM, Diagnosed Incident Cases of Endometrial Cancer with Associated Biomarker, Women, Ages ≥18 Years, N, 2020

Figure 17: 8MM, Diagnosed Incident Cases of Endometrial Cancer with HER2 Positivity by FIGO Stage, Women, Ages ≥18 Years, N, 2020

Figure 18: 8MM, Five-Year Diagnosed Prevalent Cases of Endometrial Cancer, Women, Ages ≥18 Years, N, 2020

Figure 19: Treatment Overview for Endometrial Cancer

Figure 20: Unmet Needs and Opportunities in Endometrial Cancer

Figure 21: Projected Treatment Decisions to Determine Use of Various Pipeline Agents in the First-Line Setting

Figure 22: Overview of the Development Pipeline in Endometrial Cancer

Figure 23: Key Late-Stage Trials for the Promising Pipeline Agents that GlobalData Expects be Licensed for Endometrial Cancer in the 8MM During the Forecast Period

Figure 24: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the SOC, chemotherapy

Figure 25: Analysis of the Company Portfolio Gap in Endometrial Cancer During the Forecast Period

Figure 26: Global (7MM) Sales Forecast by Country for Endometrial Cancer in 2020 and 20230

Figure 27: Sales Forecast by Class for EC in the US in 2020 and 2030

Figure 28: Sales Forecast by Class for EC in the 5EU in 2020 and 2030

Figure 29: Sales Forecast by Class for EC in Japan in 2020 and 2030

Figure 30: Sales Forecast by Class for EC in Canada in 2020 and 2030

    Pricing

Discounts available for multiple purchases.

reportstore@globaldata.com
+44 20 7947 2745

Join our mailing list

Saved reports